Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Dandachi, N; Tiran, V; Lindenmann, J; Brcic, L; Fink-Neuboeck, N; Kashofer, K; Absenger, G; Bezan, A; Cote, RJ; Datar, R; Balic, M.
Frequency and clinical impact of preoperative circulating tumor cells in resectable non-metastatic lung adenocarcinomas.
Lung Cancer. 2017; 113: 152-157.
PubMed FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Absenger Gudrun
Balic Marija
Brcic Luka
Dandachi Nadia
Fink-Neuböck Nicole
Kashofer Karl
Lindenmann Jörg
Terbuch Angelika
Tiran Verena
Gendermonitor:
Altmetrics:

Abstract:
Despite successful surgery, 30-50% of patients with resectable non-small cell lung cancer develop tumor recurrence within 5 years of surgery. In this prospective study, we performed CTC enumerations in 40 patients with non-metastatic lung adenocarcinoma (NMLA) using a size-based microfilter. Additionally, cfDNA isolated from plasma was analyzed in 35 out of 40 patients. CTCs were identified in 15 out of 40 patients (37.5%) with a range of 1-44 cells, whereas mutated cfDNA was only detected in 3 out of 35 patients (8.6%). Disease-free survival (DFS) was significantly associated with CTC positivity (log-rank p=0.025), grading (log-rank p=0.019), tumor stage (log-rank p=0.025) and lymph node status (log-rank p=0.029). Multivariate analysis, including tumor stage and grading, showed that CTC positivity (p=0.006), grading (0.039) and tumor stage (p=0.022) were independently associated with DFS. Our study found that microfilter-based CTC enumeration in NMLA patients is an independent predictor of worse DFS. The used NGS-based cfDNA characterization had limited sensitivity to be clinically informative in our study cohort. CTC assessment before surgery can thus identify NMLA patients at high risk of disease recurrence. Copyright © 2017 Elsevier B.V. All rights reserved.

© Meduni Graz Impressum